STOCK TITAN

Harmony Biosciences (HRMY) director awarded 21,872 stock options at $30.76 strike price

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. director Juan A. Sabater received a grant of stock options as part of his compensation. He was awarded options for 21,872 shares of common stock at an exercise price of $30.76 per share, giving him the right to buy shares at that price in the future. These options vest in full on the earlier of May 14, 2027 or the date of the next annual meeting after the grant, as long as he continues to serve through that vesting date. After this grant, he holds 21,872 stock options directly.

Positive

  • None.

Negative

  • None.
Insider Sabater Juan A.
Role null
Type Security Shares Price Value
Grant/Award Stock Option 21,872 $0.00 --
Holdings After Transaction: Stock Option — 21,872 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 21,872 options Stock option award to director Juan A. Sabater
Exercise price $30.76 per share Strike price for Harmony Biosciences stock options
Underlying shares 21,872 shares Common stock underlying granted options
Expiration date May 14, 2036 Option expiration for director award
Post-grant option holdings 21,872 options Total options held after reported transaction
Stock Option financial
"security_title: "Stock Option""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: "30.7600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-05-14T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest in full financial
"The stock option shall vest in full on the earlier to occur of"
annual meeting financial
"the date of the next annual meeting following the grant date"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sabater Juan A.

(Last)(First)(Middle)
C/O HARMONY BIOSCIENCES HOLDINGS, INC.
630 W GERMANTOWN PIKE, SUITE 215

(Street)
PLYMOUTH MEETING PENNSYLVANIA 19462

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$30.7605/14/2026A21,872 (1)05/14/2036Common Stock21,872$021,872D
Explanation of Responses:
1. The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
/s/ Christian Ulrich, Attorney-in-Fact05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Harmony Biosciences (HRMY) director Juan A. Sabater receive in this Form 4?

Director Juan A. Sabater received a grant of stock options for 21,872 shares at an exercise price of $30.76 per share. This is a compensation-related award, not an open-market purchase or sale, and gives him the right to buy Harmony Biosciences common stock in the future.

Is the Harmony Biosciences (HRMY) Form 4 transaction a stock buy or sell?

The Form 4 shows an acquisition through a stock option grant, not a buy or sell in the market. The transaction is coded as an award (code A), meaning options were granted as compensation rather than purchased or sold on an exchange.

What are the terms of Juan A. Sabater’s Harmony Biosciences (HRMY) stock options?

Sabater’s stock options cover 21,872 underlying common shares at a $30.76 exercise price and expire on May 14, 2036. The options vest in full on the earlier of May 14, 2027 or the next annual meeting date, subject to his continued service.

When do the Harmony Biosciences (HRMY) options granted to Juan A. Sabater vest?

The options vest in full on the earlier of May 14, 2027 or the date of the next annual meeting following the grant. Vesting depends on Sabater continuing to serve through the applicable vesting date, aligning the award with his ongoing board service.

How many Harmony Biosciences (HRMY) derivative securities does Juan A. Sabater hold after this Form 4?

Following this grant, Sabater holds 21,872 stock options directly, each tied to one share of Harmony Biosciences common stock. This total reflects the options reported in the filing and represents his derivative holdings from this specific compensation award.